VCM
STOK icon

Versant Capital Management’s Stoke Therapeutics STOK Stock Holding History

Versant Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.8K Buy
1,951
+359
+23% +$11.5K 0.01% 1197
2026
Q1 		$51.8K Hold
1,592
– – 0.01% 1215
2025
Q4 		$50.5K Hold
1,592
– – 0.01% 1087
2025
Q3 		$37.4K Hold
1,592
– – 0.01% 1200
2025
Q2 		$18.1K Buy
1,592
+1,032
+184% +$9.8K ﹤0.01% 1586
2025
Q1 		$3.72K Hold
560
– – ﹤0.01% 2133
2024
Q4 		$6.18K Buy
+560
New +$6.88K ﹤0.01% 1660

Other funds holding STOK

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
GIM
Generali Investments Management Ljubljana, Slovenia $460M AUM 29.43% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
OCWP
Owl Creek Wealth Partners Denver, Colorado $342M AUM

Versant Capital Management's STOK Position: Q2 2026 in Review

Versant Capital Management increased its Stoke Therapeutics (STOK) stake by 23% in Q2 2026, buying an estimated $11.5K and bringing the position to 1,951 shares worth $63.8K. The position accounts for 0.01% of the portfolio, ranked #1197.

Versant Capital Management first reported a position in STOK in Q4 2024 and has held it in 7 quarters since. 20 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Versant Capital Management held 1,951 shares of Stoke Therapeutics worth $63.8K as of Q2 2026.
  • Versant Capital Management bought 359 Stoke Therapeutics shares in Q2 2026, an estimated $11.5K.
  • Stoke Therapeutics made up 0.01% of Versant Capital Management's portfolio in Q2 2026, its #1197 holding.
  • Versant Capital Management first reported a position in Stoke Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 20 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.